[go: up one dir, main page]

WO2001087229A3 - Treating infections - Google Patents

Treating infections Download PDF

Info

Publication number
WO2001087229A3
WO2001087229A3 PCT/IB2001/000859 IB0100859W WO0187229A3 WO 2001087229 A3 WO2001087229 A3 WO 2001087229A3 IB 0100859 W IB0100859 W IB 0100859W WO 0187229 A3 WO0187229 A3 WO 0187229A3
Authority
WO
WIPO (PCT)
Prior art keywords
infections
combination
treating infections
antioxidants
phenolic antioxidants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000859
Other languages
French (fr)
Other versions
WO2001087229A2 (en
Inventor
Christian Matthew Westinghouse
Andries Johannes Lategan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LATWEST PHARMACEUTICALS Pty Ltd
LATWEST PHARMACEUTICALS PROPRI
Original Assignee
LATWEST PHARMACEUTICALS Pty Ltd
LATWEST PHARMACEUTICALS PROPRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LATWEST PHARMACEUTICALS Pty Ltd, LATWEST PHARMACEUTICALS PROPRI filed Critical LATWEST PHARMACEUTICALS Pty Ltd
Priority to AU2001258675A priority Critical patent/AU2001258675A1/en
Priority to PCT/IB2001/000859 priority patent/WO2001087229A2/en
Publication of WO2001087229A2 publication Critical patent/WO2001087229A2/en
Publication of WO2001087229A3 publication Critical patent/WO2001087229A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Phenolic antioxidants in combination with a delivery vehicle which avoids releasing the phenolic antioxidants in the stomach of a subject are disclosed for use in the prophylaxis and therapy of infections, especially retroviral infections by the HIV and filoviral infections by the Ebola virus. These compounds can be administered in combination with proteolytic enzymes and/or antioxidants.
PCT/IB2001/000859 2000-05-19 2001-05-17 Treating infections Ceased WO2001087229A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001258675A AU2001258675A1 (en) 2000-05-19 2001-05-17 Treating infections
PCT/IB2001/000859 WO2001087229A2 (en) 2000-05-19 2001-05-17 Treating infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2000/2492 2000-05-19
PCT/IB2001/000859 WO2001087229A2 (en) 2000-05-19 2001-05-17 Treating infections

Publications (2)

Publication Number Publication Date
WO2001087229A2 WO2001087229A2 (en) 2001-11-22
WO2001087229A3 true WO2001087229A3 (en) 2002-04-18

Family

ID=11004103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000859 Ceased WO2001087229A2 (en) 2000-05-19 2001-05-17 Treating infections

Country Status (1)

Country Link
WO (1) WO2001087229A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475526B1 (en) * 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use
JP2003201245A (en) * 2001-10-22 2003-07-18 Tanaka Ai Kk Prophylaxis for foot and mouth disease
US6855341B2 (en) 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US8168161B2 (en) * 2004-12-22 2012-05-01 Hill's Pet Nutrition, Inc. Method to promote oral health in companion animals
GB0724278D0 (en) * 2007-12-13 2008-01-30 Syntopix Ltd uses for antimicrobial agents
EP4164670A1 (en) * 2020-06-10 2023-04-19 URSAPHARM Arzneimittel GmbH Bromelain protease, bromelain, jacalin-like lectin, extract from the stem and/or the fruit of a pineapple plant, combination preparation, bromelain protease inhibitor, protein/protease mix, and glycated bromelain protein formed by exogenous non-enzymatic glycation, for use in the treatment or prophylaxis of virus infections caused by coronaviruses in a human or animal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002766A (en) * 1987-09-30 1991-03-26 Mucos Pharma Gmbh & Co. Use of catabolic enzymes for controlling the acquired immune deficiency syndrome (AIDS) and its precursors (LAS, ARC)
US5981603A (en) * 1989-07-14 1999-11-09 Vyrex Corporation Antiviral agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002766A (en) * 1987-09-30 1991-03-26 Mucos Pharma Gmbh & Co. Use of catabolic enzymes for controlling the acquired immune deficiency syndrome (AIDS) and its precursors (LAS, ARC)
US5981603A (en) * 1989-07-14 1999-11-09 Vyrex Corporation Antiviral agents

Also Published As

Publication number Publication date
WO2001087229A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2001248331A1 (en) Medicaments against viral diseases
EP1296693A4 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
MXPA02007915A (en) Aspirin triggered lipid mediators.
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
IL181909A0 (en) Phosphoindoles as hiv inhibitors
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
WO2003035686A3 (en) Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
AU3568600A (en) Antiviral composition
WO2001087229A3 (en) Treating infections
AU2002343046A1 (en) Medical dressings
WO2006034001A3 (en) Methods of treating hiv infection
WO2002060483A3 (en) Perylenequinones for use as photosensitizers and sonosensitizers
AU2636602A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2001025239A3 (en) Oxazinoquinolones useful for the treatment of viral infections
AU1201801A (en) Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
DE60214889D1 (en) Sucroseoctasulphat silber saltz
WO2000069841A3 (en) Benzofuranylaminoalcohols
WO2001066100A3 (en) Pharmaceutical composition
WO2001097749A3 (en) The use of synthetic, non-hormonal 21-aminosteroids and thereof
WO2006023774A3 (en) Plasma or serum fraction for treatment and prevention of viral infections and related conditions
WO2004096147A3 (en) Oxo-pyrimidine compounds
WO2001043730A3 (en) The treatment of convulsive states
WO2002089828A3 (en) Interferons in the treatment of ischemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP